Journal of the Chemical Society Perkin Transactions 1 · 1998 · 15 citations · 6 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyRadionuclide TherapySynthetic Medicinal ChemistryCancer ImmunotherapyTargeted Radionuclide TherapyAntibodiesAntibody-based Radionuclide TherapyAntibody-based RadiotracersBifunctional ChelatorsMedicinal Chemistry ApplicationsRadiotracer Synthesis
Immunotherapy with radiolabelled antibodies should allow fairly specific targeting of certain cancers. Although 153Sm possesses favourable radiophysical characteristics for such therapy, a lack of radiolabelling stability in vivo limits its application. Yet the use of phosphonic semi-rigid bifunctional chelating agents (BCA) can improve its stability. Syntheses of (1R*,2R*,4S*)-4-isothiocyanatocyclohexane-1,2-diamine-N,N,N′,N′-tetrakismethanephosphonic acid (4-ICMP) and (1R*,2R*,4S*)-4-isothiocyanatocyclohexane-1,2-diamine-N,N,N′,N′-tetrakisethanephosphonic acid (4-ICEP) are described in this paper. The complexing properties of these two compounds has been confirmed by labelling with 153Sm. A novel synthetic approach involving the introduction of methanephosphonic functions has also been developed.
6
Skeletal localization of samarium-153 chelates: potential therapeutic bone agents.
William Goeckeler, B. Edwards, W. A. Volkert et al. · PubMed · 1987 · 210 citations
John F. W. Keana, Jeffry S. Mann · The Journal of Organic Chemistry · 1990 · 38 citations